www.fdanews.com/articles/174727-bioventus-launches-osteoarthritis-treatment-in-taiwan
Bioventus Launches Osteoarthritis Treatment in Taiwan
January 5, 2016
Bioventus has launched in Taiwan its single-injection joint fluid Durolane for the treatment of osteoarthritis.
Durolane is indicated for the treatment of mild to moderate osteoarthritis of the knee.
The drug-device combo is based on a technology process called Nasha, which yields stabilized hyaluronic acid, a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. — Michael Cipriano